CAYMAN CHEMICAL COMPANY, INC.
30Patents
28Active
30Granted
51Portfolio score
Filing activity: Feb 14, 2006 → Jun 9, 2021 · 8 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8901319B2 | Process for the preparation of F-series prostaglandins | Emerging Cross-Sectional Technologies | 6 | Active |
| US9180116B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 6 | Active |
| US9487478B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 4 | Active |
| US9440919B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | Human Necessities | 4 | Active |
| US7674921B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | Chemistry; Metallurgy | 2 | Active |
| US9701630B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | Human Necessities | 2 | Active |
| US9908834B2 | Methods of synthesizing a prostacyclin analog | Chemistry; Metallurgy | 1 | Active |
| US8536185B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | Chemistry; Metallurgy | 1 | Active |
| US7358275B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension | Chemistry; Metallurgy | 1 | Expired |
| US9890104B2 | Amine salts of a prostacyclin analog | Chemistry; Metallurgy | 1 | Active |
| US8168400B2 | Methods and kits for detection of thromboxane A2 metabolites | Physics | 0 | Active |
| US9914725B2 | Methods of synthesizing a difluorolactam analog | Chemistry; Metallurgy | 0 | Active |
| US8105790B2 | Methods and kits for detection of thromboxane A2 metabolites | Physics | 0 | Active |
| US11345690B2 | Methods of synthesizing a difluorolactam analog | Chemistry; Metallurgy | 0 | Active |
| US8450326B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | General | 0 | Revoked |
| US9708287B2 | Chiral compounds, compositions, products and methods employing same | Human Necessities | 0 | Active |
| US9676712B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US8063240B2 | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions | Human Necessities | 0 | Active |
| US11884624B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US11066361B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US9126973B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | Chemistry; Metallurgy | 0 | Active |
| US10556862B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US9120820B2 | Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins | Physics | 0 | Active |
| US8680327B2 | Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites | Chemistry; Metallurgy | 0 | Active |
| US7585889B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.